Retired Forms Manuals

Main Content

For reference purposes, CIBMTR provides online access to manuals for retired CIBMTR and NMDP forms, Response Criteria documents, and Appendices. See the sections below for all retired content.

Retired Forms Manuals

Form Number	Form Name	Form Version	Retired Date
2000	Baseline Form Instructions (PDF)	5.0	October 2020
2000	Baseline Form Instructions (PDF)	4.0	January 2020
2000	Baseline Form Instructions (PDF)	4.0	March 2015
2000	Baseline Form Instructions (PDF)	3.0	October 2013
2003	Gene Therapy Product Form Instructions (PDF)	1.0	July 2024
2004	Infectious Disease Markers Form Instructions (PDF)	6.0	October 2025
2004	Infectious Disease Markers Form Instructions (PDF)	5.0	September 2022
2004	Infectious Disease Markers Form Instructions (PDF)	4.0	January 2020
2004	Infectious Disease Markers Form Instructions (PDF)	4.0	March 2015
2004	Infectious Disease Markers Form Instructions (PDF)	3.0	October 2013
2005	Confirmation of HLA Typing Form Instructions (PDF)	7.0	October 2025
2005	Confirmation of HLA Typing Form Instructions (PDF)	7.0	September 2022
2005	Confirmation of HLA Typing Form Instructions (PDF)	6.0	January 2020
2005	Confirmation of HLA Typing Form Instructions (PDF)	5.0	January 2017
2005	Confirmation of HLA Typing Form Instructions (PDF)	4.0	October 2013
2006	Infusion Form Instructions (PDF)	6.0	October 2025
2006	Infusion Form Instructions (PDF)	5.0	September 2022
2006	Infusion Form Instructions (PDF)	4.0	January 2020
2006	Infusion Form Instructions (PDF)	4.0	March 2015
2006	Infusion Form Instructions (PDF)	2.0	October 2013
2006	Infusion Form FAQ (PDF)	1.0	February 2010
2010	Acute Myelogenous Leukemia (AML) Pre-HCT Data Form Instructions (PDF)	3.0	July 2017
2010	Acute Myelogenous Leukemia (AML) Pre-HSCT Data Form Instructions (PDF)	2.0	October 2013
2011	Acute Lymphoblastic Leukemia (ALL) Pre-HCT Data Form Instructions (PDF)	4.0	July 2017
2013	Chronic Lymphocytic Leukemia (CLL) Pre-Infusion Form Instructions (PDF)	3.0	October 2024
2013	Chronic Lymphocytic Leukemia (CLL) Pre-HCT Data Form Instructions (PDF)	2.0	March 2015
2014	Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Pre-HCT Data Form Instructions (PDF)	3.0	May 2020
2014	Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Pre-HCT Data Form Instructions (PDF)	2.0	March 2015
2015	Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Pre-HCT Data Form Instructions (PDF)	3.0	March 2015
2016	Multiple Myeloma / Plasma Cell Disorders (PCD) Pre-HCT Data Form Instructions (PDF)	3.0	April 2021
2016	Multiple Myeloma / Plasma Cell Disorders (PCD) Pre-HCT Data Form Instructions (PDF)	3.0	January 2020
2016	Multiple Myeloma / Plasma Cell Disorders (PCD) Pre-HCT Data Form Instructions (PDF)	3.0	March 2015
2016	Multiple Myeloma / Plasma Cell Disorders (PCD) Pre-HCT Data Form Instructions (PDF)	2.0	October 2013
2018	Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data Form Instructions (PDF)	4.0	January 2019
2018	Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data Form Instructions (PDF)	5.0	October 2020
2018	Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data Form Instructions (PDF)	3.0	January 2018
2018	Hodgkin and Non-Hodgkin Lymphoma Pre-HSCT Data Form Instructions (PDF)	2.0	October 2013
2019	Waldenstrom's Macroglobulinemia / Lymphoplasmacytic Lymphoma (MAC) Pre-HCT Data Form Instructions (PDF)	3.0	March 2015
2028	Aplastic Anemia Pre-HCT Data Form Instructions (PDF)	2.0	October 2020
2028	Aplastic Anemia Pre-HCT Data Form Instructions (PDF)	1.0	March 2015
2030	Sickle Cell Disease Pre-Infusion Form Instructions (PDF)	4.0	October 2025
2030	Sickle Cell Disease Pre-Infusion Form Instructions (PDF)	3.0	October 2024
2034	X-Linked Lymphoproliferative Syndrome (XLP) Pre-HCT Data Form Instructions	3.0	March 2015
2037	Leukodystrophies Pre-Infusion Form Instructions (PDF)	3.0	July 2024
2039	Hemophagocytic Lymphohistiocytosis (HLH) Pre-HCT Data Form Instructions (PDF)	3.0	March 2015
2046	Fungal Infection Pre-Infusion Data (PDF)	4.0	May 2018
2058	Thalassemia Pre-Infusion Form Instructions (PDF)	1.0	July 2024
2100	Post-HCT Follow-Up (PDF)	8.0	October 2023
2100	Post-HCT Follow-Up (PDF)	7.0	September 2022
2100	Post-HCT Follow-Up (PDF)	6.0	July 2021
2100	100 Day Post-HCT Data Form Instructions (PDF)	5.0	October 2020
2100	100 Day Post-HCT Data Form Instructions (PDF)	4.0	July 2018
2100	100 Days Post-HCT Data Form Instructions (PDF)	3.0	January 2017
2110	Acute Myelogeneous Leukemia (AML) Post-HCT Data Form Instructions (PDF)	3.0	July 2017
2110	Acute Myelogenous Leukemia (AML) Post-HSCT Data Form Instructions (PDF)	2.0	October 2013
2111	Acute Lymphoblastic Leukemia (ALL) Post-HCT Data Form Instructions (PDF)	3.0	July 2017
2113	Chronic Lymphocytic Leukemia (CLL) Post-Infusion Form Instructions (PDF)	3.0	October 2024
2113	Chronic Lymphocytic Leukemia (CLL) Post-HCT Data Form Instructions (PDF)	2.0	March 2015
2114	Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data Form Instructions (PDF)	3.0	May 2020
2114	Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data Form Instructions (PDF)	2.0	March 2015
2115	Juvenile Myelomonocytic Leukemia (JMML) Post-HCT Data Form Instructions (PDF)	3.0	March 2015
2116	Multiple Myeloma / Plasma Cell Disorders (PCD) Post-HCT Data Form Instructions (PDF)	3.0	April 2021
2116	Multiple Myeloma / Plasma Cell Disorders (PCD) Post-HCT Data Form Instructions (PDF)	3.0	January 2020
2116	Multiple Myeloma / Plasma Cell Disorders (PCD) Post-HCT Data Form Instructions (PDF)	3.0	March 2015
2116	Multiple Myeloma / Plasma Cell Leukemia Post-HSCT Data Form Instructions (PDF)	2.0	October 2013
2118	Hodgkin and Non-Hodgkin Lymphoma Post-HCT Data Form Instructions (PDF)	3.0	January 2018
2118	Hodgkin and Non-Hodgkin Lymphoma Post-HCT Data Form Instructions (PDF)	2.0	October 2013
2119	Waldenstrom's Macroglobulinemia / Lymphoplasmacytic Lymphoma (MAC) Post-HCT Data Form Instructions (PDF)	3.0	March 2015
2128	Aplastic Anemia Post-HCT Data Form Instructions (PDF)	2.0	October 2020
2128	Aplastic Anemia Post-HCT Data Form Instructions (PDF)	1.0	March 2015
2130	Sickle Cell Disease Post-Infusion Form Instructions (PDF)	4.0	October 2025
2130	Sickle Cell Disease Post-Infusion Form Instructions (PDF)	3.0	October 2024
2134	X-Linked Lymphoproliferative Syndrome (XLP) Post-HCT Data Form Instructions (PDF)	3.0	March 2015
2137	Leukodystrophies Post-Infusion Form Instructions (PDF)	3.0	July 2024
2139	Hemophagocytic Lymphohistiocytosis (HLH) Post-HCT Data Form Instructions (PDF)	3.0	March 2015
2146	Fungal Infection Post-Infusion Data (PDF)	3.0	May 2018
2158	Thalassemia Post-Infusion Form Instructions (PDF)	1.0	July 2024
2199	Donor Lymphocyte Infusion Form Instructions (PDF)	1.0	October 2025
2200	Six Months to Two Years Post-HCT Data Form Instructions (PDF)	3.0	January 2017
2300	Greater Than Two Years Post-HCT Data Form Instructions (PDF)	3.0	January 2017
2400	Pre-TED Form Instructions (PDF)	10.0	October 2025
2400	Pre-TED Form Instructions (PDF)	9.0	September 2022
2400	Pre-TED Form Instructions (PDF)	8.0	October 2021
2400	Pre-TED Form Instructions (PDF)	7.0	January 2021
2400	Pre-TED Form Instructions (PDF)	6.0	May 2020
2400	Pre-TED Form Instructions (PDF)	5.0	January 2020
2400	Pre-TED Form Instructions (PDF)	4.0	January 2017
2400	Pre-TED Form Instructions (PDF)	3.0	October 2013
2402	Pre-TED Disease Classification Form Instructions (PDF)	9.0	October 2025
2402	Pre-TED Disease Classification Form Instructions (PDF)	8.0	October 2024
2402	Pre-TED Disease Classification Form Instructions (PDF)	7.0	April 2024
2402	Pre-TED Disease Classification Form Instructions (PDF)	6.0	September 2022
2402	Pre-TED Disease Classification Form Instructions (PDF)	5.0	October 2020
2402	Pre-TED Disease Classification Form Instructions (PDF)	4.0	May 2020
2402	Pre-TED Disease Classification Form Instructions (PDF)	3.0	January 2020
2402	Pre-TED Disease Classification Form Instructions (PDF)	2.0	January 2018
2402	Pre-TED Disease Classification Form Instructions (PDF)	1.0	July 2017
2450	Post-TED Form Instructions (PDF)	8.0	October 2025
2450	Post-TED Form Instructions (PDF)	7.0	July 2024
2450	Post-TED Form Instructions (PDF)	6.0	September 2022
2450	Post-TED Form Instructions (PDF)	5.0	October 2021
2450	Post-TED Form Instructions (PDF)	4.0	January 2020
2450	Post-TED Form Instructions (PDF)	3.0	January 2017
2540	Tepadina® Supplemental Data Collection Form Instructions (PDF)	1.0	April 2019
2542	Mogamulizumab Supplemental Data Collection (PDF)	1.0	January 2024
2556	Myelofibrosis Pre-HCT Data	1.0	May 2020
2557	Myelofibrosis Post-HCT Data	1.0	May 2020
2800	Log of Appended Documents Form Instructions (PDF)	2.0	March 2015
General Instructions Section 11	Log of Appended Documents	N/A	August 2014
2804	CIBMTR Recipient ID Assignment Form Instructions (PDF)	6.0	October 2025
2804	CIBMTR Recipient ID Assignment Form Instructions (PDF)	5.0	October 2019
2804	CIBMTR Recipient ID Assignment Form Instructions (PDF)	4.0	March 2015
2814	Indictation Form Instructions (PDF)	4.0	July 2024
2814	Indication Form Instructions (PDF)	2.0	April 2019
2900	Recipient Death Data Form Instructions (PDF)	5.0	October 2025
2900	Recipient Death Data Form Instructions (PDF)	4.0	October 2021
2900	Recipient Death Data Form Instructions (PDF)	3.0	January 2019
2900	Recipient Death Data Form Instructions (PDF)	2.0	January 2017
2900	Recipient Death Data Form Instructions (PDF)	1.0	March 2015
3500	Subsequent Neoplasms Form Instuctions (PDF)	2.0	October 2025
3500	Subsequent Neoplasms Form Instructions (PDF)	1.0	July 2021
3501	Pregnancy Form Form Instructions (PDF)	1.0	April 2025
4000	Cellular Therapy Essential Data Pre-Infusion Form Instructions (PDF)	9.0	July 2023
4000	Cellular Therapy Essential Data Pre-Infusion Form Instructions (PDF)	8.0	September 2022
4000	Cellular Therapy Essential Data Pre-Infusion Form Instructions (PDF)	7.0	July 2021
4000	Cellular Therapy Essential Data Pre-Infusion Form Instructions (PDF)	6.0	January 2021
4000	Cellular Therapy Essential Data Pre-Infusion Form Instructions (PDF)	5.0	January 2020
4000	Cellular Therapy Essential Data Pre-Infusion Form Instructions (PDF)	4.0	January 2018
4000	Cellular Therapy Essential Data Pre-Infusion Form Instructions (PDF)	3.0	July 2017
4003	Cellular Therapy Product Form Instructions (PDF)	5.0	July 2023
4003	Cellular Therapy Product Form Instructions (PDF)	4.0	February 2022
4003	Cellular Therapy Product Form Instructions (PDF)	3.0	January 2021
4003	Cellular Therapy Product Form Instructions (PDF)	2.0	January 2020
4003	Cellular Therapy Product Form Instructions (PDF)	1.0	January 2019
4006	Cellular Therapy Infusion Data Form Instructions (PDF)	6.0	July 2023
4006	Cellular Therapy Infusion Data Form Instructions (PDF)	5.0	February 2022
4006	Cellular Therapy Infusion Data Form Instructions (PDF)	4.0	January 2021
4006	Cellular Therapy Infusion Data Form Instructions (PDF)	3.0	January 2020
4006	Cellular Therapy Infusion Data Form Instructions (PDF)	2.0	January 2018
4006	Cellular Therapy Infusion Data Form Instructions (PDF)	1.0	July 2017
4100	Cellular Therapy Essential Data Follow-Up Form Instructions (PDF)	8.0	July 2023
4100	Cellular Therapy Essential Data Follow-Up Form Instructions (PDF)	7.0	February 2022
4100	Cellular Therapy Essential Data Follow-Up Form Instructions (PDF)	6.0	July 2021
4100	Cellular Therapy Essential Data Follow-Up Form Instructions (PDF)	5.0	January 2021
4100	Cellular Therapy Essential Data Follow-Up Form Instructions (PDF)	4.0	January 2020
4100	Cellular Therapy Essential Data Follow-Up Form Instructions (PDF)	3.0	October 2018
4100	Cellular Therapy Essential Data Follow-Up Form Instructions (PDF)	2.0	January 2018
4100	Cellular Therapy Essential Data Follow-Up Form Instructions (PDF)	1.0	July 2017
N/A	Supplemental Report Form Manuals Study R02-09 AML/ALL Study R02-09 MDS R02-09 General Instructions AML-M3/APML Intravenous Busulfan Study - Supplemental Data Intravenous Busulfan Study - Supplemental Form 2509	N/A	September 2013
N/A	TED Manual (PDF)	N/A	January 2008
N/A	NMDP Forms Instruction Manual (PDF)	N/A	December 2007
N/A	CIBMTR Data Management Manual (PDF)	N/A	December 2007
N/A	CIBMTR Registration Instruction Manual (PDF)	N/A	December 2007

Retired Response Criteria

Disease Response Criteria	Retired Date
Acute Lymphoblastic Leukemia (ALL) Response Criteria	July 2017
Acute Monoblastic Leukemia (AML) Response Criteria	July 2017
Hodgkin and Non-Hodgkin Lymphoma (LYM) Response Criteria	January 2018
Multiple Myeloma (MM) / Plasma Cell Disorders (PCD) Response Criteria	January 2020
Myelodysplastic Syndrome (MDS) / Myeloproliferative Neoplasm (MPN) Response Criteria	May 2020
Amyloidosis Response Criteria	May 2022
Neuroblastoma Response Criteria	October 2025

Appendices

Appendix Letter	Appendix Name
Table of Contents (PDF)	Appendices Table of Contents
Appendix A (PDF)	Abbreviations and Definitions
Appendix B (PDF)	Glossary of Terms
Appendix C (PDF)	Cytogenetic Assessments
Appendix C (PDF)	CIBMTR Data Collection Forms
Appendix D (PDF)	How to Distinguish Infusion Types
Appendix D (PDF)	Unique ID Assignment Form (CRID), Form 2804
Appendix E (PDF)	Public Health Authority (PHA) Status
Appendix F (PDF)	Validation Ranges
Appendix G (PDF)	Continuous Process Improvement (CPI) and Procedures for Non-Compliance
Appendix H (PDF)	Summary of CIBMTR On-Site Data Audit Program
Appendix H (PDF)	MDS & MPN Subtypes
Appendix I (PDF)	Ethnicity and Race (Retired 2025)
Appendix I (PDF)	Ethnicity and Race
Appendix J (PDF)	Reporting Comorbidities
Appendix K (PDF)	Key Fields
Appendix L (PDF)	Karnofsky/Lansky Performance Status
Appendix L (PDF)	Karnofsky/Lansky Performance Status (Retired 2025)
Appendix M (PDF)	The Hematopoietic Cell Transplant-Co-morbidity Index (HCT-CI)
Appendix M (PDF)	HCT Critical Data Fields
Appendix N (PDF)	Response Evaluation Criteria in Solid Tumors (RECIST)
Appendix O (PDF)	How to Distinguish Infusion Types
Appendix O (PDF)	Cellular Therapy Critical Fields
Appendix P (PDF)	Definition of Product
Appendix Q (PDF)	United States Abbreviations
Appendix R (PDF)	Cytogenetic Abbreviations and Terminology
Appendix S (PDF)	Multiple Donor Chimerism
Appendix T (PDF)	Pre-HCT Treatment for Lymphoma
Appendix U (PDF)	Helpful Hints for Reporting Co-Existing Diseases
Appendix V (PDF)	Multiple Myeloma - Defining What Baseline to Use When Determining the Best Response to HSCT
Appendix W (DOC)	Tracking Disease Status for Multiple Myeloma
Appendix Y (PDF)	Critical Fields
Appendix Z (PDF)	Primary Disease and Disease Inserts Due